Table 1.

Summary of the TNBC neoantigen candidates

Patient/cell line	HLA allele	Predicted binder*	Actual binder†	Immunogenic‡	Displayed by the tumor§
SW1360	HLA-A*24:02	4	2	0	n.d
SW2163	HLA-A*02:01	10	9	4	n.d
	HLA-A*24:02	9	4	0	n.d
SW2183	HLA-A*02:01	14	14	10	n.d
	HLA-A*24:02	20	8	0	n.d
SW2388	HLA-A*03:01	9	7	0	n.d
MDA-MB-231	HLA-A*02:01	27	21	16	1

*As determined by NetMHC 4.0 program.

†Binding assay evaluated using cell-based binding assays.

‡Reactivity as determined by intracellular IFN-γ in CD8+T cells by FACS.

§Reactivity as determined by intracellular IFN-γ in CD8+T cells by FACS and CTL assay.

n.d, not determined; TNBC, triple-negative breast cancer.